Management and Outcomes of Patients with Acute Coronary Syndromes in Australia and New Zealand 2000–2007

Gender difference in treatment and mortality of patients with ST-segment elevation myocardial infarction admitted to Victorian public hospitals: A retrospective database study

“…46 Calls have been made for increased treatment for higher risk patients to maximise outcomes. 16,17 Women have also been reported in other research to have higher short-term mortality after PCI and a higher 30-day morbidity and mortality than men. 47 Mortality rates secondary to CABG are also higher for women in the short-term.…”

“…16 Through a number of reports arising from these studies, an issue identified as of critical significance for the future reduction of morbidity and mortality from ACS was access to treatment. 13,16 Other studies have reported 30-40% of patients did not receive reperfusion therapy to which they were eligible, 17,18 which was similar to under-treated proportions of STEMI populations reported in North America 19 and Europe. 20 Despite the consistency in ACS guidelines across the United States, 21 Europe, 22 and Australia and New Zealand, 23,24 knowledge translation into clinical practice is often suboptimal.…”

The underutilisation of dual antiplatelet therapy in acute coronary syndrome

“…In Australia, government funding of clopidogrel for all ACS patients was not available until shown use of this drug in the medically managed cohort to be low (15-30%) [27]. However, even with government funding now available, the increase in uptake has been limited.…”

Challenges and solutions in medically managed ACS in the Asia-Pacific region: Expert recommendations from the Asia-Pacific ACS Medical Management Working Group

“…The continuous improvement in quality of treatment in hospitals that follow guidelines is well established in ACS [30,31]. Nevertheless, the translation of best practice recommendations and their implementation to 'real-world' patient care is often poor.…”